Literature DB >> 26014156

Age-Related Morbidity and Mortality with Cytoreductive Surgery.

Madalyn G Peters1, Edmund K Bartlett2, Robert E Roses2, Rachel R Kelz2, Douglas L Fraker2, Giorgos C Karakousis2.   

Abstract

INTRODUCTION: Cytoreduction and intraperitoneal chemotherapy (IPC) are increasingly considered in older patients. We sought to better characterize the influence of age on 30-day outcomes following this procedure.
METHODS: The ACS NSQIP database was queried for patients who underwent IPC and a concurrent intra-abdominal operation (2005-2012). Thirty-day death and serious morbidity (DSM) was the primary outcome. Trends in DSM by age were defined using Joinpoint regression. Univariate and multivariate logistic regression identified factors associated with DSM.
RESULTS: In 1085 patients, DSM increased at a significant rate after age 50 (0.6 %/year, p = 0.001). Patients ≥60 (n = 376) represented 35 % of the study population. Age ≥60 years was independently associated with DSM (odds ratio [OR] 1.6, p = 0.001). The older patient population (≥60 years) experienced 44 % morbidity and 3.2 % mortality. In these patients, preoperative weight loss, low preoperative albumin, splenectomy, intraoperative transfusion, contaminated or dirty wound classification, and prolonged operative time were all independently significantly associated with increased DSM. In the absence of these factors (n = 45), the DSM rate was 11 %. Rates of DSM increased to 33, 63, and 100 % in patients with 1 factor, 2-3 factors, and 4 or more factors (n = 14; p < 0.001), respectively. Venous thromboembolism, sepsis, postoperative bleeding, and respiratory complications were significantly more common among those aged 60 years and older (p < 0.05 each).
CONCLUSIONS: The risk of DSM increases with age in patients undergoing cytoreduction and IPC. Risk can be stratified using a limited number of patient and operative characteristics.

Entities:  

Mesh:

Year:  2015        PMID: 26014156     DOI: 10.1245/s10434-015-4624-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for resectable peritoneal metastases is feasible in elderly patients.

Authors:  Walid Ezzedine; Diane Mege; Mathilde Aubert; Julie Duclos; Rémy Le Huu Nho; Igor Sielezneff; Nicolas Pirro
Journal:  Updates Surg       Date:  2021-02-06

2.  Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy.

Authors:  Toshiyuki Kitai; Kenya Yamanaka; Yuya Miyauchi; Masahiro Kawashima
Journal:  Int J Clin Oncol       Date:  2017-01-04       Impact factor: 3.402

Review 3.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.

Authors:  Andrew D Newton; Edmund K Bartlett; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

4.  Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study.

Authors:  Job P van Kooten; Arvind Oemrawsingh; Nadine L de Boer; Cornelis Verhoef; Jacobus W A Burger; Eva V E Madsen; Alexandra R M Brandt-Kerkhof
Journal:  Ann Surg Oncol       Date:  2020-06-10       Impact factor: 5.344

Review 5.  Improving outcomes for older women with gynaecological malignancies.

Authors:  Lucy Dumas; Alistair Ring; John Butler; Tania Kalsi; Danielle Harari; Susana Banerjee
Journal:  Cancer Treat Rev       Date:  2016-08-29       Impact factor: 12.111

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.